Lose weight with science backed coaching, support and medicine

Wegovy contains semaglutide as its active ingredient. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it acts in the same way as certain hormones produced by your body when you have eaten. Semaglutide helps you to feel fuller for longer after eating, resulting in you eating less food. When used in combination with a healthy lifestyle and diet semaglutide results in weight loss.

Wegovy and Ozempic both contain semaglutide as their active ingredients. Both have the same effect on your body. However, Ozempic is licensed only for the management of type 2 diabetes. Wegovy, on the other hand, is specifically licensed for weight loss.

Semaglutide is used as an injection, once a week. You will normally start using semaglutide at a low dose, increasing up to a maintenance dose, gradually. Semaglutide is also available as an oral tablet, under the brand name Rybelsus. Rybelsus is taken once daily, 30 minutes before food. You are advised to follow the dosage instruction provided to you by your healthcare provider.

Off label prescribing is when a medication is prescribed for a purpose other than what it is licensed to be used for. On occasion, our healthcare providers at Now Patient, may prescribe Ozempic “off-label”, for weight loss, if Wegovy is unavailable. We will only prescribe off-label if it is safe to do so.

Common side effects of semaglutide include:

• Feeling sick, being sick
• Stomach pain, heartburn
• Diarrhoea, constipation
• Headache, dizziness, tiredness
• Burping, bloating, wind

Side effects will tend to reduce as your body adjusts to the medication. Speak to one of our healthcare professionals if you need further medical support.

Serious side effects of semaglutide include:

• ‍Pancreatitis
• Gallstones
• Hypoglycemia
• Allergic reactions
• Diabetic retinopathy
• Palpitations

Get medical attention right away if you experience any of the serious side effects.

Yes. All medications undergo rigorous clinical trials and testing before they are approved to be used for medicinal purposes in the U.K. In the U.K. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates all medication. Ozempic was approved for the treatment of type 2 diabetes in 2017, Rybelsus was approved for type 2 diabetes in 2019 and Wegovy was approved in 2023. At Now Patient, you are able to contact our clinical team for support and advice when needed.

Wegovy and Ozempic should be stored in a refrigerator, between 2°-8°C, before they are first used. They should not be frozen. Once you have started to use either Wegovy or Ozempic, they may be stored in the refrigerator or in a dark place below 30°C. Pens should be discarded after 6 weeks, in accordance with the manufacturer’s recommendation. Rybelsus tablets do not need to be stored in a refrigerator. They can be stored at room temperature between 20-25°C, in a dry safe place away from moisture.

Injection Pens remain in cold storage while at the pharmacy, and are transported using cold-chain packaging, ensuring cold-chain regulations are met throughout the delivery. Cold-chain packaging used by pharmacies ensures medication is maintained at 2-8°C for up to 72 hours

If, for any reason, pens have not been refrigerated at 2-8°C, before their initial use, they will remain suitable to use for up to 56 days after the date of dispatch. Please speak to one of our dedicated team members if you have any queries.

Injection Pens will remain suitable for use until their expiry date if stored in the refrigerator. The expiry date can be found on the packaging your pen is provided in and on the pen itself. You are advised to store the pen in the refrigerator after you have started using it, but not past 56 days from the date of first use.

Our cold chain packaging at Now Patient is designed to maintain a refrigerator temperature of 2-8°C, for up to 72 hours. You can still use your pen if it arrives at a temperature above 2-8°C for up to 56 days after the date of dispatch.

People using semaglutide for weight loss should expect to lose a minimum of 5% of their body weight within 12 weeks of treatment starting, but most people should start to see weight loss within the first few weeks. The amount of time it takes to work however, will vary for each person. If you do not see a 5% loss of body weight after using semaglutide for 12 weeks, speak to one of our specialist dietitians or nutritionists for further advice.

At Now Patient we offer:

• Video Consultations
• Online Assessments
• Dietitian Appointments
• Pharmacy First
• New Medicine service
• NHS prescriptions
• Pharmacogenomic testing
• Health Test Kits

Semaglutide pens contain 4 doses, with one dose for each week. Each pen will last 4 weeks. Semaglutide tablets, once daily, come in packs of 30 and will last you 30 days.

Yes. All medications undergo rigorous clinical trials and testing before they are approved to be used for medicinal purposes in the U.K. In the U.K. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates all medication use. The MHRA has approved the long-term use of semaglutide for the treatment of obesity.

Also, here at Now Patient, our team of clinicians will work with you closely to provide you with a safe and effective service, tailored to you as an individual.

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist as its active ingredient. Mounjaro is approved for the treatment of diabetes and weight loss. The dual action of Mounjaro enhances the secretion of insulin when blood sugar levels are high and prevents the secretion of glucagon. This helps to better control blood sugar levels in patients with Type 2 diabetes. Mounjaro also helps to control appetite and slows emptying of the stomach, leading to weight loss in those patients with or without Type 2 diabetes.

Mounjaro is given as a subcutaneous injection, under the skin. It is normally injected directly into the abdomen, thigh, or upper arm. You will start with a low dose to minimise possible side effects, increasing gradually, based on how you respond to treatment. Here at Now Patient, our team of clinicians will provide you with advice on how to administer your injections correctly.

Common side effects of Mounjaro include:

• Feeling sick, being sick
• Diarrhoea, constipation
• Stomach pain, indigestion

These often resolve over time as your body adjusts to treatment. Other, less common side effects include:

• Pancreatitis
• Gallstones and inflammation of the gallbladder
• Severe hypoglycemia

You are advised to monitor for any serious side effects. Speak to our healthcare team if you need further advice.

Mounjaro helps to regulate appetite and delay gastric emptying, leading to a reduction in food intake and an increased feeling of fullness. Mounjaro should be used in combination with changes in lifestyle, diet and exercise to achieve the best results for weight loss.

Mounjaro is not recommended in people with a family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2.

Mounjaro is not recommended during pregnancy or breastfeeding as its safety and efficacy has not been established. Women are advised to use effective birth control during treatment.

Mounjaro may interact with sulfonylureas and insulin which are used for the treatment of Type 2 diabetes, increasing the risk of low blood sugar levels. Mounjaro may also affect the absorption of oral medication due to its effect on delaying gastric emptying. Your clinician may adjust your dose of Mounjaro based on these interactions and monitor your progress closely.

Mounjaro is stored in the refrigerator at 2°-8°C, but can be kept at room temperature, 30°C, for up to 30 days from when it is dispensed and once being used.

If you forget to administer a dose of Mounjaro, administer it as you can within 4 days after missing the dose. However, if more than 4 days have passed, do not administer the missed dose. Administer your next dose on your next scheduled day. Remember to resume your regular once a week dosing schedule.

If you think you have used too much Mounjaro by taking two doses, please contact us immediately. You may experience gastrointestinal symptoms such as nausea and vomiting. We will schedule a call with one of our healthcare providers who will discuss your symptoms.

The recommended starting dose is 2.5mg in the first month, increased to 5 mg in the second month. Here at Now Patient our healthcare team will help you find the most appropriate dose for you as an individual, based on how you respond to your treatment.

Yes. You can change treatment from both Wegovy or Ozempic directly to Mounjaro. You will need to speak to one of our healthcare professionals, for them to decide the most appropriate dose. This will however also depend on the availability of Mounjaro, as currently not all doses are available in the U.K.